You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

AZTREONAM Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Aztreonam patents expire, and what generic alternatives are available?

Aztreonam is a drug marketed by Fresenius Kabi Usa, Hikma, and Hospira. and is included in three NDAs.

The generic ingredient in AZTREONAM is aztreonam. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the aztreonam profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Aztreonam

A generic version of AZTREONAM was approved as aztreonam by FRESENIUS KABI USA on June 18th, 2010.

  Try a Trial

Drug patent expirations by year for AZTREONAM
Drug Prices for AZTREONAM

See drug prices for AZTREONAM

Recent Clinical Trials for AZTREONAM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Meiji Seika Pharma Co., Ltd.Phase 3
National Cancer Institute (NCI)Phase 1
Qianfoshan HospitalN/A

See all AZTREONAM clinical trials

Pharmacology for AZTREONAM
Medical Subject Heading (MeSH) Categories for AZTREONAM

US Patents and Regulatory Information for AZTREONAM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa AZTREONAM aztreonam INJECTABLE;INJECTION 065439-002 Jun 18, 2010 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Hospira AZTREONAM aztreonam INJECTABLE;INJECTION 206517-002 Nov 8, 2021 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Hikma AZTREONAM aztreonam INJECTABLE;INJECTION 065286-001 Mar 23, 2011 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Fresenius Kabi Usa AZTREONAM aztreonam INJECTABLE;INJECTION 065439-003 Jun 18, 2010 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Fresenius Kabi Usa AZTREONAM aztreonam INJECTABLE;INJECTION 065439-001 Jun 18, 2010 RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for AZTREONAM

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Gilead Sciences Ireland UC Cayston aztreonam EMEA/H/C/000996
Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Authorised no no no 2009-09-21
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.